
YM150 study 7
rivaroxaban study 1
rivaroxaban study 2
rivaroxaban study 3
apixaban study 4
LY517717 study 5
razaxaban study 6
fraction of patients with VTE
dose
0.0
0.1
0.2
0.3
0.4
0.5
0.6
10 20 30 40 50 60
10 20 30 40
5 10 15 20
50 100 150
50 100 150 200